Clinical Efficacy of Anlotinib Combined with Docetaxel in Treatment of Driver-negative Advanced Non-small Cell Lung Cancer
Objective To explore the effect of combined anlotinib and docetaxel in the treatment of non-small cell lung cancer.Methods A total of 120 patients with non-small cell lung cancer admitted to Jilin Cancer Hospital from June 2022 to July 2023 were selected as the study objects and divided into two groups with sixty cases each by ran-dom ball-touching method.The control group was treated with docetaxel and the study group was treated with docetaxel and anlotinib.The clinical efficacy,epithelial cell adhesion molecule(EP-CAM),soluble intercellular adhe-sion molecule-1(SICAM1),the level of cellular adhesion molecule(CAM)in serum and the incidence of adverse reac-tions were compared between the two groups.Results The disease remission rate in the study group was 43.33%,higher than 21.67%in the control group,the difference was statistically significant(χ2=6.419,P=0.011).After treat-ment,the levels of EP-CAM,SICAM1 and CAM in the study group were lower than those in the control group,and the differences were statistically significant(all P＜0.05).The incidence rate of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion The combina-tion of anlotinib and docetaxel in the treatment of driver negative non-small cell lung cancer can reduce tumor mark-ers and reduce the risk of adverse reactions.
NETL
NSTL
万方数据
